Abstract: Highly active antiretroviral therapy has signifi cantly reduced HIV-related morbidity and mortality. Increasingly, fi xed-dose antiretroviral combinations with equal or greater potency than traditional antiretrovirals, along with fewer side effects, reduced toxicity, and simplifi ed dosing convenience are being utilized. Tenofovir-emtricitabine (TDF-FTC) represents one of the more recent fi xed-dose combinations. In combination with either a ritonavir-boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor, TDF-FTC is a preferred choice in recent treatment guidelines on the basis of demonstrated potency in randomized clinical trials, one-pill-a-day dosing convenience, and relatively low toxicity. In addition, the drug is active against hepatitis B virus. Caution must be exercised in patients with renal insuffi ciency, or when the drug is used with certain other drugs. This manuscript reviews the use of TDF-FTC in the treatment of HIV.
Introduction
Health care practitioners and researchers have been fi ghting human immunodefi ciency virus (HIV) infection for over two decades. During this time, signifi cant progress has been made in understanding the pathogenesis, clinical presentation, and epidemiology of the disease. The advent of antiretroviral therapy has signifi cantly improved the prognosis and quality of life of persons living with HIV. Currently, over 20 antiretroviral drugs have been approved by the Food and Drug Administration (FDA) for the treatment of HIV infection. These agents are classifi ed into: (a) nucleoside/nucleotide reverse transcriptase inhibitors (NRTI/NtRTI), (b) non-nucleoside reverse transcriptase inhibitors (NNRTI), (c) protease inhibitors (PI), and (d) fusion inhibitors. Despite the increased number of choices, issues of adherence, tolerability, long-term toxicity, and drug resistance remain to be some of the major challenges in the management of HIV. To address these problems, advances have been made in the development of novel agents and fi xed-dose combination treatment regimens with greater potency, lower toxicity, and improved convenience for patients.
Central among the factors affecting adherence and compliance in the treatment of HIV/AIDS are antiretroviral dosing frequency and pill burden. The effort toward reduced dosing frequency and pill burden has led to the fi rst FDA-approved, once a day, single pill treatment for HIV that contains three antiretroviral medications -efavirenz, tenofovir, and emtricitabine. However, many patients must continue to take more complicated and toxic HIV therapeutic regimens due to drug intolerance or drug resistance (Masquelier et al 2005; Ross et al 2007) . Tenofovir disoproxil fumarateemtricitabine (TDF-FTC) is a once-daily, fi xed-dose NtRTI/NRTI combination that has demonstrated effi cacy in well-designed clinical trials with good follow up (Pozniak et al 2005; Gallant et al 2006; Pozniak et al 2006) . TDF-FTC combines the benefi ts of less toxicity, dosing simplicity, and favorable pharmacokinetic properties (Table  1) . This article will review the current use of this versatile NtRTI/NRTI combination in the management of HIV patients. To better understand the characteristics of TDF-FTC, it is essential to examine its components, TDF and FTC ( (Schinazi et al 1992; Frampton et al 2005) . Studies indicate that FTC is effi cacious in combination with other antiretrovirals in reducing HIV viral loads in both treatment-naïve and experienced patients (Molina et al 2000; Benson et al 2004; Saag et al 2004; Molina et al 2005) . FTC can be taken without regard to food consumption and is completely eliminated via the kidneys, so dosage adjustment is required in case of renal insuffi ciency (Sax et al 2007) . Potential drug interactions and toxicity, including mitochondrial toxicities and dyslipidemias, are nearly absent. The most common side effects include headache, insomnia, diarrhea, nausea, vomiting, and rash (Benson et al 2004; Saag et al 2004) . FTC may cause skin hyperpigmentation of the palms and soles in African and African American patients.
Tenofovir-emtricitabine (Truvada ® )
TDF-FTC is a once daily treatment composed of TDF and FTC to be used in combination with other antiretroviral drugs. The TDF-FTC co-formulation contains 300 mg of TDF and 200 mg of FTC administered orally in one tablet that has . TDF-FTC with the NNRTI efavirenz represents the most simplifi ed antiretroviral dosing schedule yet, consisting of two pills or a single threedrug, fi xed-dose combination tablet (Atripla ® ) once a day. When combined with one of three currently recommended ritonavir-boosted PIs, the daily pill burden is a total of 4 or 5 pills. The only other preferred NRTI fi xed-dose combination pill, zidovudine (ZDV) +3TC (Combivir ® ), is given twice a day. Other once-a-day NRTI combinations include fi xed-dose abacavir + lamivudine (Epzicom ® ) and didanosine with either TDF or stavudine (D4T) extended release. Abacavir + lamivudine, while effi cacious and well tolerated, has somewhat less clinical trial data supporting its use and at this time remains an alternate recommendation in guidelines. Didanosine combined with either TDF or D4T extended has a higher incidence of toxicity and is not recommended as 
TDF-FTC effi cacy
Gilead study 934 was the pivotal effi cacy trial for the TDF-FTC combination (Pozniak et al 2006) . This randomized, open-label, noninferiority trial enrolled 517 antiretroviralnaïve, HIV-infected patients to receive either TDF + FTC and efavirenz or ZDV + 3TC and efavirenz. The primary endpoint was the proportion of patients with an HIV RNA level Ͻ400 copies/mL in patients without baseline nonnucleoside resistance. Through week 96, signifi cantly more patients receiving TDF + FTC achieved and maintained an HIV RNA level Ͻ400 copies/mL (75% vs 62%). The TDF + FTC group also demonstrated a signifi cantly greater increase in CD4+ lymphocyte counts (270 vs 237 cells/mm 3 ; p = 0.036).
Another clinical trial, Gilead 903, a randomized, placebocontrolled study, compared TDF or D4T in combination with 3TC and efavirenz in 602 treatment-naïve subjects. This study demonstrated equivalence in the percentage of subjects with HIV RNA Ͻ50 copies/mL at week 48 and through 144 with less lipoatrophy and more favorable lipid profi les in the TDF arm (Gallant et al 2004) . In treatment-experienced patients, the TDF-FTC is commonly used as guided by drug resistance testing, but the relative benefi t of the combination relative to other NRTI/NtRTI choices is diffi cult to gauge and will depend on many factors, including HIV genotypic or phenotypic susceptibility scores, drug interactions, and compliance. It is well documented that 3TC benefi ts patients with the RT M184V/I mutation that are incompletely suppressed virologically, possibly as a result of impairing viral fi tness or residual virologic activity, and likely this holds true of FTC as well.
Therapeutic use of TDF-FTC among special populations
No effi cacy differences have been identifi ed between male and female patients (Gilead Sciences 2006) . Suffi cient data is not available to examine differences among different races and ethnic groups and geriatric populations. Because both TDF and FTC are excreted via the kidneys, modifi cation of TDF-FTC dosage and special caution is necessary when treating patients with renal impairments (Table 3) TDF and FTC are both active against HBV in vitro, in case series (Benhamou et al 2003) , and in a small controlled clinical trial with HIV-HBV coinfected subjects (Peters MG et al 2006) , but are not approved for that indication. While FTC has no activity against lamivudine-resistant HBV strains, in HIV co-infected patients with a positive HBeAg, the inclusion of TDF in the HIV regimen resulted in a significant reduction of viral load, including those with lamivudineresistant strains (Nelson et al 2003; Dore et al 2004) . TDF also may be active against strains of HBV resistant to the NtRTI adefovir and be more potent as well (Qi et al 2007; Lacombe et al 2007) . In its most recent guideline, the American Association for the Study of Liver Disease (AASLD) has also included TDF and FTC as one of the drugs that may be used to treat HIV-HBV co-infected patients (Benhamou 2006; Lok and McMahon 2007) . While the effi cacy and safety of TDF-FTC has not been thoroughly studied in the treatment of HIV-HBV co-infection, several studies have indicated that discontinuation of TDF-FTC in HBV-infected patients may result in severe and acute exacerbation or fl are up of the hepatitis (Bessesen et al 1999; Bartlett and Gallant 2005) . Liver function tests should be monitored for at least several months in HIV/HBV co-infected patients who are suspended from treatment with TDF-FTC. Because of the risk of HIV resistance with two-drug therapy, if co-infected Review of tenofovir-emtricitabine patients require treatment, other agents such as adefovir or pegylated interferon should be used.
TDF-FTC is excreted in breast milk and should not be used while nursing (Gilead Sciences 2006). The effects of TDF-FTC in pregnant and nursing mothers need to be investigated further in light of its future use.
Resistance and cross-resistance
Resistance to TDF is conferred by the reverse transcriptase (RT) K65R and/or K70E mutations (Van Rompay et al 2007) . K65R can be selected by TDF as well as the NRTIs abacavir and didanosine. This mutation is relatively uncommon. In antiretroviral-naïve patients, there is little baseline resistance to TDF. More than two of certain thymidine analog mutations (TAMS -RT M41L, L210W, and T215Y/F) confer that resistance to TDF may be present. TDF does not select for TAMs. The RT M184V/I mutation is selected by both FTC and 3TC, though perhaps slightly less readily by the former, and leads to complete cross-resistance between the two. Interestingly, the M184V/I mutation can partially re-sensitize HIV that contains TAMs or the K65R mutation to TDF. Using FTC or 3TC with TDF may result in a somewhat higher barrier to drug resistance than seen with TDF alone, though several triple NRTI studies using TDF with FTC or 3TC have demonstrated that this theoretical benefi t has limits.
A recent literature review indicated that resistance to FTC-TDF is relatively infrequent (Muñoz de Benito and Arribas Lopez 2006). Among the two Gilead clinical trials, a signifi cant difference was seen in the proportion of patients receiving experiencing virologic rebound on therapy that developed the K65R mutation, with 22% (8 of 36) of patients in the 903 study and no patients in the 934 study developing the mutation (Pozniak et al 2006) . The reason for this discrepancy is unclear, though follow up in 903 was longer. The incidence of M184V/I in the TDF arm was 39% and 14%, respectively, but since the incidence of virologic rebound was small, these do not represent large numbers.
Toxicity and adverse reactions
TDF-FTC is generally well tolerated, with few side effects as noted above for the individual compounds. Lactic acidosis and hepatomegaly with steatosis, including fatal cases, have been reported with most other nucleosides but have not been reported to occur with TDF-FTC, to our knowledge (Gilead Sciences 2006) . TDF and FTC are principally eliminated via the kidneys. Like the known nephrotoxic NtRTIs cidofovir and adefovir, TDF is extracted from the blood plasma by the human renal organic anion transporters (hOAT1 and hOAT3), which has suggested the possibility of renal tubular toxicity (Uwai et al 2007) . While the data concerning the clinical relevance on this are somewhat inconsistent (Mocroft et al 2007; Gayet-Ageron et al 2007; Pozniak et al 2006; Gallant et al 2007) , it appears that renal tubular toxicity, and occasionally Fanconi's syndrome (renal tubular injury with severe hypophosphatemia, phosphoturia, and glycosuria), serious hyperkalemia (Shepp et al 2007) , or acute interstitial nephritis may develop with TDF or TDF-FTC use. The majority of these cases occurred in patients with underlying systemic vascular insult, low glomerular filtration rates (GFR)/ chronic renal failure, or in patients taking nephrotoxic agents. Certain genetic haplotypes may be associated in some cases (Izzedine et al 2006) , though a number of cases have occurred in patients without identifi able risk factors. (Bartlett and Gallant 2005; Gilead Sciences 2006) Because certain protease inhibitors, including lopinavir and atazanavir, increase the serum levels of TDF by as much as 25%, this could be a risk factor for nephrotoxicity (Kiser et al 2007; Goicoechea et al 2007) , and extra caution is advised. The drug should be used only with great caution in patients with reduced GFR. All HIV infected patients, particularly those on TDF, should have baseline and yearly determination of GFR using either the CockcroftGault or modification of diet in renal disease (MDRD) method, as well as regular assessments of serum blood urea nitrogen and creatinine. Consideration should be given to monitoring serum phosphate in those on TDF as well. Significant GFR or serum phosphate decline should prompt further evaluation and strong consideration for discontinuation of TDF (Ristig et al 2002; Murphy et al 2003; Schaaf et al 2003; Barrios et al 2004; James 2004; Gilead Sciences 2006) . It is not well-elucidated if TDF-induced renal tubular toxicity routinely results in phosphaturia or glycosuria, so the absence of these cannot be relied upon to exclude a role for TDF in a patient's renal failure.
Subclinical renal phosphate wasting could possibly contribute to a decrease in bone mineral density that was reported in a study conducted among treatment-naïve patients who were treated with TDF in Gilead 903 (Cassetti et al 2006 (Cassetti et al , 2007 . A decrease in bone mineral density at the lumbar spine and hip, especially between weeks 24 and 48, was evident but was non-progressive through 288 weeks. Thus, monitoring of bone mineral density should be considered in patients with history of, or risk factors for, pathologic fractures. To the knowledge of the authors, no study has examined the benefi t of calcium and vitamin D supplementation or bisphosponates in this setting.
Use of TDF-FTC has been associated with fewer overall adverse effects than D4T-3TC or ZDV-3TC. Compared with ZDV, TDF is associated with a lower frequency of anemia (4% vs 9%, respectively; p = 0.02) , and compared with D4T, TDF is associated with fewer lipid abnormalities.
Both TDF and abacavir containing regimens are associated with less severe side effects or improvements in lipoatrophy, a reduction in subcutaneous fat tissue, particularly in the face and extremities. This condition may result from mitochondrial toxicity induced in particular by the thymidine analog NRTIs, ZDV and D4T. In Gilead 934, limb fat, measured by whole-body DEXA at weeks zero and 96, was significantly greater in the TDF + FTC + efavirenz group versus the ZDV + 3TC + efavirenz group (7.7 vs 5.5 kg; p Ͻ 0.001) (Pozniak et al 2006) . A similar lipoatrophy benefit with TDF was observed in an analysis restricted to African or African American study participants . An interesting twist to this story was suggested by AIDS Clinical Trial Group (ACTG) study 5142, which confirmed greater limb fat loss with D4T as compared with AZT, and ZDV as compared with TDF containing regimens; but in addition, NNRTI containing regimens were associated with greater fat loss than PI containing regimens, independent of which NRTi/NtRTI was used (Haubrich et al 2007) . The mechanism for an apparent lipoatrophy-potentiating effect of NNRTIs on NRTIs is not understood at this time, but this study should prompt further investigation.
Drug interactions
It is assumed that drug interaction for TDF-FTC is the same when administered combined or dosed alone as TDF or FTC. Any medications that reduce renal function may increase concentration of FTC and TDF. No drug interactions with clinical consequences are known for FTC. As mentioned above, co-administration of TDF with certain protease inhibitors, including atazanavir, lopinavir/ritonavir, and darunavir (TMC-114)/ritonavir (Hoetelmans et al 2007) results in increased plasma levels of TDF and, in the case of atazanavir and lopinavir/ritonavir, reduced protease inhibitor troughs. While no dose adjustment is recommended when TDF is used with these drugs (Bartlett and Gallant 2005; DHHS 2006) , in cases where baseline protease resistance mutations have modestly raised the concentration of the drug required to inhibit the virus, this effect of TDF could be signifi cant. Atazanvir should always be ritonavir boosted (atazanavir 300 mg should be boosted with ritonavir 100 mg) when used with TDF.
TDF should be used very cautiously with didanosine due to increased rates of adverse reactions including peripheral neuropathy and pancreatitis. This is likely a result of a drug interaction resulting in a 40%-50% increase in plasma didanosine levels (Pruvost et al 2005) and/or intracellular drug interactions. In addition, use of TDF with didanosine has also been associated with paradoxical CD4 declines or less than robust CD4 increases in some, but not all studies (Barrios 2005; Karrer et al 2005; Torti et al 2007) . These results are reminiscent of those seen in studies combining didanosine with hydroxyurea. If co-administration of didanosine and TDF is necessary, didanosine dose should be adjusted and patients should be closely monitored for didanosine-related adverse reactions. The recommended didanosine dose for patients weighing Ͼ60 kg in this setting Review of tenofovir-emtricitabine is 250 mg; however, there is no adequate information for patients weighing below 60 kg (Gilead Sciences 2006).
Conclusion
There is suffi cient data to recommend the use of TDF-FTC in the treatment of HIV. It is recommended as a preferred and alternative treatment of choice in both treatment-naïve and experienced patients. In addition to its demonstrated effi cacy, TDF-FTC also provides signifi cant advantages in terms of few side effects, low long-term toxicity, once daily dosing, few drug interactions, useful anti-HBV activity, and a relatively high genetic barrier relative to other NRTIs/NtRTIs (Table 4) . Caution must be exercised in patients with reduced renal function and when the drug is used with certain other antiretrovirals. 
